The efferocytosis receptor TREM2 is a prime example, as several groups have shown that TREM2 deficiency exacerbates liver inflammation and fibrosis in MASLD models (118, 119), suggesting that TREM2 agonism may be an effective therapeutic strategy. Here, TREM2 is linked to metabolic dysfunction-associated steatotic liver disease.